Respiratory failure & ventilation
Diagnostic performance of Pneumonia multiplex polymerase chain reaction (PCR) in critically ill immunocompromised patients
Authors' conclusion
The use of mPCR in the diagnosis of pneumonia in immunocompromised patients shortens the time required to obtain results, and is particularly effective in eliminating the presence of multi-resistant germs.
Study context
- Population
- Critically ill immunocompromised patients admitted for acute respiratory failure requiring invasive ventilation, deep respiratory specimen <48 h after mechanical ventilation
- Participants
- 114 participants
- Comparison
- BioFire FilmArray Pneumonia Panel multiplex PCR vs conventional culture
- Outcome
- Diagnostic performance of BFPP mPCR compared with CC
Methodological detailsretrospective, single-centre
- Retrospective
- Single-centre
Performance
As reported in the abstract
Diagnostic performance of mPCR vs CC
Sensitivity of rapid techniques (mPCR) vs conventional culture (CC)
89%
Specificity of rapid techniques (mPCR) vs CC
83%
PPV of rapid techniques (mPCR) vs CC
52%
NPV of rapid techniques (mPCR) vs CC
98%
Secondary outcomes
Therapeutic impact of mPCR results
- mPCR enabled antibiotic therapy to be modified, mainly de-escalation
- 17.5%
mPCR positivity rate
- mPCR positivity rate
- 36.8%
- Enterobacteria among identifications
- 51%
- Median turnaround time
- between 2h30 and 4 h
Concordance between mPCR and CC
- Complete concordance between the two techniques
- 84.2%
Original publication
Diagnostic performance of Pneumonia multiplex PCR in critically ill immunocompromised patients. Crit Care. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →